Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02290821 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 215
- Enrollment target
NCT02290821 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 215 participants.
The verdict
NCT02290821, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 215 participants
- Enrollment target
Study Summary
This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with acute blunt trauma injuries.
Interventions
- DRUG placebo
- DRUG Placebos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02290821
The ClinicalTrials.gov registry entry for NCT02290821 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02290821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02290821 about?
NCT02290821 is a clinical study titled "Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries". This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with acute blunt trauma injuries.
What is the current status of trial NCT02290821?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 215 participants. The study started on 2014-12. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02290821?
The interventions under investigation include: placebo (DRUG), Placebos (DRUG).
Who is sponsoring clinical trial NCT02290821?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.